Avalo Therapeutics (AVTX) Debt to Equity (2016 - 2025)
Avalo Therapeutics (AVTX) has disclosed Debt to Equity for 10 consecutive years, with $0.0 as the latest value for Q2 2025.
- For the quarter ending Q2 2025, Debt to Equity changed N/A year-over-year to $0.0, compared with a TTM value of $0.0 through Jun 2025, changed N/A, and an annual FY2024 reading of $0.0, changed N/A over the prior year.
- Debt to Equity was $0.0 for Q2 2025 at Avalo Therapeutics, up from $0.0 in the prior quarter.
- Across five years, Debt to Equity topped out at $1.42 in Q4 2021 and bottomed at -$8.14 in Q3 2022.
- Average Debt to Equity over 5 years is -$1.59, with a median of -$0.62 recorded in 2022.
- Peak annual rise in Debt to Equity hit 186.86% in 2022, while the deepest fall reached 186.86% in 2022.
- Year by year, Debt to Equity stood at $1.42 in 2021, then crashed by 186.86% to -$1.24 in 2022, then crashed by 35.22% to -$1.67 in 2023, then soared by 100.16% to $0.0 in 2024, then soared by 30.75% to $0.0 in 2025.
- Business Quant data shows Debt to Equity for AVTX at $0.0 in Q2 2025, $0.0 in Q1 2025, and $0.0 in Q4 2024.